Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 25

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 25
---
 existing products and
procedures are, and any new products or procedures we develop and commercialize will be, subject to intense competition. The industry
in which we operate is competitive, subject to change and sensitive to the introduction of new products, procedures or other market activities
of industry participants. Our ability to compete successfully will depend on our ability to continue to train surgeons on the GelrinC
hydrogel implant procedure and gain their acceptance of the procedure, develop additional products and procedures to improve GelrinC
implementation and expand our product offerings that reach the market in a timely manner, receive adequate coverage and reimbursement
from third-party payors and provide products that are easier to use, safer, less invasive and more effective than the products and procedures
of our competitors.

We compete with large, diversified
medical device and pharmaceutical companies, including Vericel and others. We also compete with smaller companies similar to us. We also
face potential competition from many different sources, including academic institutions, governmental agencies, and public and private
research institutions.

At any time, these competitors
and other potential market entrants may develop new products, procedures or treatment alternatives that could render our products obsolete
or uncompetitive. In addition, one or more of such competitors may gain a market advantage by developing and patenting competitive products,
procedures or treatment alternatives earlier than we can, obtaining regulatory clearances or approvals more rapidly than we can or selling
competitive products at prices lower than ours. If medical research were to lead to the discovery of alternative therapies or technologies
that improve or cure tissue regeneration as an alternative to surgery, the use of pharmaceuticals or breakthrough bio-technological innovations
or therapies, our profitability could suffer through a reduction in sales or a loss in market share to a competitor. The discovery of
methods of prevention or the development of other alternatives to tissue repair therapies could result in decreased demand for our product
and, accordingly, could have a material adverse effect on our business, financial condition and results of operations. Many of our current
and potential competitors have substantially greater sales and financial resources than we do. These competitors may also have more established
distribution networks, a broader offering of products, entrenched relationships with surgeons and distributors or greater experience
in launching, marketing, distributing and selling products or treatment alternatives.

We also compete with our
competitors to engage the services of independent sales agents, both those presently working with us and those with whom we hope to work
with as we expand. In addition, we compete with our competitors in